Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess Reactogenicity and Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Compared to Tritanrix™-HepB/Hiberix™ (Control) in Healthy Infants (2,4,6 Months Age), After a Hepatitis B Birth Dose

NCT00317135 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00317135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess Reactogenicity and Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Compared to Tritanrix™-HepB/Hiberix™ (Control) in Healthy Infants (2,4,6 Months Age), After a Hepatitis B Birth Dose
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
December 11, 2003
Completion date
October 23, 2004
Enrollment
500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, hepatitis b, tetanus, whole cell pertussis